> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Two Biotronik Cardiac Rhythm Devices Approved
- URL: https://www.fdaweb.com/two-biotronik-cardiac-rhythm-devices-approved/
- Published: 2019-03-14T12:00:00.000Z
- Updated: 2026-09-15T01:12:37.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5143613

FDA has approved Biotronik’s Acticor and Rivacor high-voltage cardiac rhythm management (CRM) device lines for treating patients with cardiac arrhythmias. The devices are: Rivacor VR-T, Rivacor DR-T, Rivacor HF-T QP, Acticor DX, Acticor CRT-DX Bipolar and Acticor CRT-DX.

They are designed with advanced diagnostic and therapeutic capabilities to provide physicians with more comprehensive therapy options when treating cardiac patients with varying disease states and comorbidities, the company says. The Acticor and Rivacor devices are the smallest and slimmest 3 Tesla, magnetic resonance-conditional CRM devices on the market, it says. They also feature “extended longevity” — nearly 15 years for the VR-T, 13.5 years for DR-T, 14 years for DX and nine years for CRT.

Both device lines, Biotronik says, are equipped with home monitoring, “which is associated with a greater than 60% reduction in all-cause mortality due to heart failure and a 36% reduction in hospitalization for worsening heart failure. They also feature MRI AutoDetect technology, which automatically recognizes when a patient enters an MRI environment and adjusts therapy for the duration of the scan.”